Detailed introduction and marketing information of recombinant DNA-derived coagulation factor VIII concentrate (recombinant)

Recombinant DNA-derived coagulation factor VIII concentrate (Altuviio) is an innovative treatment option specifically designed for patients with hemophilia A. Its main function is to replace missing or defective coagulation factor VIII to effectively prevent and treat bleeding. Hemophilia A is a genetic disease in which patients lack clotting factor VIII, causing the blood to fail to work properly when it needs to clot, resulting in excessive and unexpected bleeding. Patients with severe disease often experience spontaneous bleeding for no obvious reason, while patients with mild disease often experience heavy bleeding after surgery or severe trauma. Therefore, timely and effective coagulation factor supplementation is crucial for these patients.

Altuviio is designed to be injected once a week, providing continued protection and effectively reducing the risk of bleeding. As the first highly sustained factor VIII replacement therapy approved by the FDA, Altuviio's efficacy and safety are based on data from two Phase III clinical studies, XTEND-1 and XTEND-Kids. These studies show that Altuviio performs well in preventing bleeding and also works well in treating acute bleeding, providing patients with a reliable treatment option.

The use of Altuviio not only improves patients' quality of life, but also provides protection for their daily activities. Through weekly infusions, patients do not have to visit the doctor frequently, thereby reducing the medical burden and giving them more autonomy and freedom in life. The introduction of this new coagulation factor replacement therapy marks an important development in the treatment of hemophilia.

To sum up,Altuviio provides an effective coagulation factor VIII replacement treatment option for hemophilia A patients. Its once-weekly injection frequency not only reduces the risk of bleeding, but also improves the patient's quality of life. The advent of this innovative product not only brings new hope for clinical treatment, but also opens up a new way for self-management of hemophilia patients.

As of now, there is no recombinant DNA-derived coagulation factor VII concentrate in China. If patients need this drug, they can seek help from regular overseas medical consultants to understand it.

Reference link: https://www.drugs.com/altuviiio.html